Kate Rochlin
Seminars
Thursday 17th September 2026
Industry Leaders Panel Discussion:
4:30 pm
- What is the remaining first-in-class opportunity for bispecifics/multispecifics in cancer? Where do engagers fit into different lines of treatment and relapsed or resistant patients?
- How are bispecifics/multispecific formats and targets being optimized to expand applications across a breadth of solid tumors beyond blood cancer?
- Understanding how bispecifics/multispecifics can accelerate into clinical trials more quickly in the oncology setting, how this drug modality fits into the broader continuum of care for cancer, and how this translates into remaining market opportunity for cancer
- Developing or repurposing bispecifics/multispecifics for immunology to achieve sustained immune cell depletion and recognizing the different risk-benefit profiles in cancer versus immunology
- Recognizing the higher benchmark for safety data in the immunology/autoimmune disease setting compared to oncology
Wednesday 16th September 2026
Beyond CD3: Harnessing Gamma Delta T-cells for Efficient Targeting Across Cancer & Autoimmunity
12:30 pm
- Exploring gamma delta T cells as a differentiated immune effector population to overcome limitations associated with classical CD3-based T-cell engagers
- Solving the scarcity issue: Novel TCE design or mechanism to expand gamma-delta T-cells in vivo
- Leveraging preclinical evidence and clinical insight from gamma delta T-cell therapies to inform safety, efficacy, and broader applicability
